These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3780832)

  • 1. Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion.
    Autret E; Marchand S; Breteau M; Grenier B
    Eur J Clin Pharmacol; 1986; 31(1):79-83. PubMed ID: 3780832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.
    Canis F; Husson MO; Turck D; Vic P; Launay V; Ategbo S; Vincent A; Courcol RJ
    J Antimicrob Chemother; 1997 Mar; 39(3):431-3. PubMed ID: 9096197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic parameters of amikacin in cystic fibrosis children.
    Grenier B; Autret E; Marchand S; Thompson R
    Infection; 1987; 15(4):295-9. PubMed ID: 3117703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suction blisters technique in amikacin diffusion through interstitial fluid in cystic fibrosis.
    Vaillant L; Autret E; Marchand S; Lorette G; Grenier B
    Dev Pharmacol Ther; 1991; 16(1):29-32. PubMed ID: 1879249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
    Caceres Guido P; Perez M; Halac A; Ferrari M; Ibarra M; Licciardone N; Castaños C; Gravina LP; Jimenez C; Garcia Bournissen F; Schaiquevich P
    Pediatr Pulmonol; 2019 Nov; 54(11):1801-1810. PubMed ID: 31402602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
    Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
    J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
    Grenier B; Gilly R
    Presse Med; 1984 Mar; 13(13):815-8. PubMed ID: 6231602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Lau WK; Young LS; Osher AB; Dooley RR
    Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin pharmacokinetics in pediatric patients with malignancy.
    Cleary TG; Pickering LK; Kramer WG; Culbert S; Frankel LS; Kohl S
    Antimicrob Agents Chemother; 1979 Dec; 16(6):829-32. PubMed ID: 533263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.
    Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC
    J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
    Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
    Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases.
    Bataillon V; Lhermitte M; Lafitte JJ; Pommery J; Roussel P
    J Antimicrob Chemother; 1992 May; 29(5):499-508. PubMed ID: 1624390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
    Stutman HR; Shalit I; Marks MI; Greenwood R; Chartrand SA; Hilman BC
    Am J Med; 1987 Apr; 82(4A):142-5. PubMed ID: 3555028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
    Strandvik B; Malmborg AS; Alfredson H; Ericsson A
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and clinical experience with amikacin. A new aminoglycoside antibiotic].
    Lode H; Grunert K; Koeppe P; Langmaack H
    Dtsch Med Wochenschr; 1976 Sep; 101(36):1312-7. PubMed ID: 782811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis.
    Reed MD; Aronoff SC; Stern RC; Yamashita TS; Myers CM; Friedhoff LT; Blumer JL
    Pediatr Pulmonol; 1986; 2(5):282-6. PubMed ID: 3774385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ceftazidime absorption into bronchial secretions in mucoviscidosis patients].
    Berthelot G; Lenoir G; Grenier B; Tournier G; Sardet A; Steru D; Bergogne-Berezin E
    Pathol Biol (Paris); 1985 May; 33(5):430-4. PubMed ID: 3897974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification in the pharmacokinetics of amikacin during development.
    Lanao JM; Dominguez-Gil A; Dominguez-Gil AA; Málaga S; Crespo M; Nuño F
    Eur J Clin Pharmacol; 1982; 23(2):155-60. PubMed ID: 7140805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.